Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type
EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT, CHROMOSOME 2q31.2 DELETION SYNDROME
About this trial
This is an interventional treatment trial for EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT focused on measuring Arteries, ultrasonography, Ehlers Danlos syndrome, Cardiovascular disease, beta adrenergic antagonists
Eligibility Criteria
Inclusion Criteria: Proven disease, No betablocker at inclusion if previous CV event Exclusion criteria: Criteria of not inclusion for the RIGHTEOUS group: Patient having already presented an arterial break or a dissection and treated(handled) by bétâ-blocking(surrounding). Against indication in the use of CELIPROLOL: Unchecked cardiac insufficiency by the treatment cardiogenic shock BAV of 2nd and 3rd not sailed degrees angor of Prinzmetal disease of the sine bradycardia pheochromocytoma untreated low blood pressure sentimentality in the CELIPROLOL Antecedent of anaphylactic reaction myasthenia treatment by FLOCTAFENINE ( Idarac), Sultopride ( interactions ) In these two cases, the patient can be included in the group followed by troop. Criteria of not inclusion for both groups: Refusal to participate in the study. Impossibility to move. Pregnancy Woman in age to procreate without means of effective contraception.
Sites / Locations
Arms of the Study
Arm 1
Experimental
Treatment
Celiprolol